ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Waxman To Introduce Reauthorization Bill Next Month, Intends To Complete Action By Session End

July 22, 1988

AACI Adopts Plan To Step Up Cancer Issues Involvement

January 25, 1980

“If We Had More Resources, It’s A Fantastic Time” For Cancer Research

May 12, 1995

Breast Cancer Action Plan Committee Outrages By Plans for $14M In NCI Funds

August 1, 1997

Drug Shortage A Boon For Levoleucovorin; Price Is 60 Times Higher Than Leucovorin

January 16, 2009

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014